New biologics and targeted therapies in systemic lupus: From new molecular targets to new indications. A systematic review

Serum interferon-α levels and IFN type I-stimulated genes score perform equally to assess systemic lupus erythematosus disease activity

(2022) François Chasset et al.   ANNALS OF THE RHEUMATIC DISEASES

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

(2022) Richard A Furie et al.   ANNALS OF THE RHEUMATIC DISEASES

Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis

(2022) David Jayne et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials

(2022) Eric F Morand et al.   Lancet Rheumatology

Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials

(2022) Ian N Bruce et al.   ANNALS OF THE RHEUMATIC DISEASES

TLR7 gain-of-function genetic variation causes human lupus

(2022) Grant J. Brown et al.   NATURE

Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus

(2022) Joan T. Merrill et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus

(2022) Victoria P. Werth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus

(2022) Richard A. Furie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE)

(2021) Daniel J Wallace et al.   ANNALS OF THE RHEUMATIC DISEASES

Hydroxychloroquine in systemic and autoimmune diseases: Where are we now?

(2021) Alina Dima et al.   JOINT BONE SPINE

Phase 2, Randomized, Placebo-Controlled Trial of Dapirolizumab Pegol in Patients with Moderate-to-Severe Active Systemic Lupus Erythematosus

(2021) Richard A Furie et al.   RHEUMATOLOGY

OP0023 GENERATION OF PT101, A HIGHLY SELECTIVE IL-2 MUTEIN FOR TREATMENT OF AUTOIMMUNE DISEASES

(2021) J. Visweswaraiah et al.   ANNALS OF THE RHEUMATIC DISEASES

Filgotinib or Lanraplenib in Moderate to Severe Cutaneous Lupus Erythematosus: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study

(2021) Victoria P Werth et al.   RHEUMATOLOGY

Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus

(2021) Jodi L. Karnell et al.   Science Translational Medicine

Practical management of patients on hydroxychloroquine

(2021) Christophe Richez et al.   JOINT BONE SPINE

Interleukin-2 and regulatory T cells in rheumatic diseases

(2021) Antonios G. A. Kolios et al.   Nature Reviews Rheumatology

Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial

(2020) Hermine I Brunner et al.   ANNALS OF THE RHEUMATIC DISEASES

Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus

(2020) Lennard Ostendorf et al.   NEW ENGLAND JOURNAL OF MEDICINE

Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis

(2020) Richard Furie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Receptor-gated IL-2 delivery by an anti-human IL-2 antibody activates regulatory T cells in three different species

(2020) Ufuk Karakus et al.   Science Translational Medicine

Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus

(2019) Richard Furie et al.   JOURNAL OF CLINICAL INVESTIGATION

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

(2019) Antonis Fanouriakis et al.   ANNALS OF THE RHEUMATIC DISEASES

The essential role of costimulatory molecules in systemic lupus erythematosus

(2019) Z X Xiao et al.   LUPUS

Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date

(2019) Renaud Felten et al.   Drug Design Development and Therapy

T-cell expression of Bruton’s tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia

(2019) Simo Xia et al.   Cellular & Molecular Immunology

Type I interferon gene signature test–low and –high patients with systemic lupus erythematosus have distinct gene expression signatures

(2019) PZ Brohawn et al.   LUPUS

Trial of Anifrolumab in Active Systemic Lupus Erythematosus

(2019) Eric F. Morand et al.   NEW ENGLAND JOURNAL OF MEDICINE

The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials

(2018) Renaud Felten et al.   AUTOIMMUNITY REVIEWS

Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial

(2018) Michelle Rosenzwajg et al.   ANNALS OF THE RHEUMATIC DISEASES

A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease

(2018) Laurence B. Peterson et al.   JOURNAL OF AUTOIMMUNITY

Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

(2017) Richard Furie et al.   Arthritis & Rheumatology

Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity

(2017) Alexander N. R. Weber et al.   Frontiers in Immunology

Engagement of SLAMF3 enhances CD4+T-cell sensitivity to IL-2 and favors regulatory T-cell polarization in systemic lupus erythematosus

(2016) Denis Comte et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus

(2015) Tobias Alexander et al.   ANNALS OF THE RHEUMATIC DISEASES

Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms

(2015) A. Pellerin et al.   EMBO Molecular Medicine

Treatment of Lupus Nephritis With Abatacept: The Abatacept and Cyclophosphamide Combination Efficacy and Safety Study

(2014)   Arthritis & Rheumatology

Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-Blind, Phase III Study

(2013) Eduardo F. Mysler et al.   ARTHRITIS AND RHEUMATISM

Costimulatory Pathways: Physiology and Potential Therapeutic Manipulation in Systemic Lupus Erythematosus

(2013) Nien Yee Kow et al.   Clinical & Developmental Immunology

Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve-Month, Randomized, Double-Blind Study

(2013) Richard Furie et al.   Arthritis & Rheumatology

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

(2012) Brad H. Rovin et al.   ARTHRITIS AND RHEUMATISM

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

(2010) J. T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

(2009) Joan T. Merrill et al.   ARTHRITIS AND RHEUMATISM